Roughly three in four cancer survivors report cognitive difficulties after treatment, and three in four of those want help for it — but one widely cited study found only 3% had ever received cognitive support. A newly published oncologist's guide shows how survivorship programs can close that gap without adding staff.
"Chemo brain" has been part of survivor vocabulary for decades, but it has rarely had a standard place in survivorship follow-up. That is starting to change. In late 2025, JCO Oncology Practice published a practical, flowchart-based guide instructing oncologists on how to screen for and manage cancer-related cognitive impairment (CRCI) in routine care.[1] A separate 2026 analysis of 13 clinical guidelines from seven professional societies found that while cognitive, sexual, and psychological problems in survivors are increasingly acknowledged in guidance documents, most of that guidance remains only moderate in quality and inconsistent on how programs should actually implement it.[2] Together, the two publications describe a familiar pattern for survivorship leaders: the clinical need is well established, but the operational infrastructure to act on it consistently has lagged behind.
The scale of that need is larger than many programs assume. Cancer-related cognitive impairment affects memory, processing speed, attention, and executive function, and subjective reports of these symptoms range from roughly 21% to as high as 90% among breast cancer patients, depending on the population and how symptoms are measured.[3] The JCO Oncology Practice guide puts the figure as high as 75% of cancer patients experiencing some degree of CRCI, with symptoms persisting well beyond active treatment in about one in four.[1] In a widely cited survey of 1,610 survivors, 75% reported treatment-related cognitive complaints — and among those, 75% said they wanted support, primarily cognitive training, psychological support, and structured physical activity. Only 3% had ever received it.[4]
Why Cognitive Symptoms Are So Easy to Miss in Follow-Up
Part of the reason CRCI has been slow to enter routine survivorship screening is a mismatch between how it presents and how clinicians have traditionally tested for it. Standard neurocognitive instruments, including screens like the Mini-Mental State Exam, were built to detect impairment severe enough to suggest dementia or major neurocognitive disorder. CRCI is typically far more subtle — a survivor who scores normally on a formal cognitive battery may still struggle daily with word-finding, multitasking, or sustaining attention at work.[1][3] That mismatch has historically left clinicians without a clear tool to confirm what patients are already telling them, and it has made it easier to attribute complaints to fatigue, anxiety, or "getting older" rather than to a distinct, treatment-related syndrome.
Risk is not evenly distributed. Chemotherapy exposure carries the strongest association with cognitive complaints, and dose intensity matters; endocrine therapy, particularly tamoxifen, is independently associated with cognitive symptoms in hormone-sensitive breast cancer; and risk climbs further with older age, lower baseline cognitive reserve, coexisting anxiety or depression, fatigue, poor sleep, and elevated inflammatory markers such as C-reactive protein and interleukin-6.[3] The current mechanistic understanding centers on treatment-induced neuroinflammation, which helps explain why CRCI so often clusters with fatigue, mood symptoms, and sleep disruption rather than appearing as an isolated complaint.[1] For survivorship programs, that clustering is useful: a survivor flagged for fatigue or distress on an existing screening tool is also a survivor worth asking about cognition.
What the New Clinical Guidance Recommends
The JCO Oncology Practice guide is notable for what it does not require before a clinician acts. Rather than waiting for a formal neuropsychological evaluation, the authors recommend routine screening for all patients, with a structured conversation and initial intervention triggered as soon as a screen is positive.[1] Validated patient-reported tools designed specifically for this population — the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) and PROMIS cognitive function measures — are the recommended starting point, reserving full neuropsychological testing for survivors whose symptoms are severe, worsening, or diagnostically unclear.[1][3]
Once a survivor screens positive, the guidance favors a stepped approach. Lower-risk, broadly beneficial interventions come first: aerobic exercise, resistance training, yoga, mindfulness-based stress reduction, and structured cognitive rehabilitation that teaches compensatory strategies and psychoeducation about what CRCI is and is not.[1][3] Pharmacologic options are considered next for persistent, functionally significant symptoms, though the evidence base remains limited; psychostimulants such as methylphenidate and modafinil have shown modest benefit in some trials, donepezil failed to outperform placebo in a major study, and memantine's role is still being defined.[3] Dose reduction, treatment modification, or referral to neuropsychology or neurology is reserved for more severe or treatment-limiting cases.[1] The throughline across the guidance is that survivors should not be left to simply cope with cognitive symptoms as an unavoidable cost of treatment, nor should programs wait for a definitive diagnostic label before offering support.
Why the Gap Persists — And What Survivors Actually Want
The 2026 guideline-quality analysis helps explain why, even with reasonably clear clinical direction, implementation has lagged: across the 13 guidelines reviewed, 92% were rated only moderate quality, and the authors describe cognitive, sexual, and psychological concerns collectively as "a cluster of silent struggles" that guidance documents acknowledge in principle more consistently than health systems operationalize in practice.[2] That finding lines up with what survivors themselves report. A 2026 survey of 724 survivors found that nearly half needed interventions for cognitive difficulties "often" or "very often," including well after treatment ended, and identified clear preferences for how that support should be delivered: written self-management materials ranked highest (71%), followed by face-to-face group sessions (53%) and oral self-management resources (50%), with most survivors preferring these interventions be offered six to twelve months after treatment rather than during it.[5]
That preference data matters operationally. It suggests that a meaningful share of the unmet need identified in these studies can be addressed with low-cost, scalable resources — structured written materials, guided self-management, and light-touch group programming — rather than requiring every survivor to be routed into individual neuropsychology referrals a program may not have the capacity to sustain. The gap, in other words, is not primarily a resource-intensity problem. It is a structural one: screening isn't happening consistently, and even where survivors are willing to raise cognitive concerns, there is often no defined next step waiting for them.
Building a Screening Pathway Without New Headcount
Closing this gap doesn't require a dedicated neurocognitive clinic or a new full-time role. It requires treating CRCI screening the way a well-built survivorship program already treats other treatment-driven risks: as a scheduled, triggered step in the care plan rather than something a clinician has to remember to raise.
In practice, that starts with capturing the exposures that drive risk — chemotherapy regimen and cumulative dose, endocrine therapy type and duration, and coexisting fatigue, distress, or sleep-disruption flags already captured on existing screening tools — as structured fields in the survivorship record. From there, a brief, validated cognitive screen (FACT-Cog or a PROMIS short form) can be built into the same intake and follow-up visits where distress and fatigue are already assessed, rather than added as a separate appointment. A positive screen should route automatically to a tiered response: written self-management and psychoeducational materials as the default first step, given how strongly survivors prefer that format; a referral pathway to exercise, cognitive rehabilitation, or group programming for survivors who want more structured support; and a clear escalation route to neuropsychology for symptoms that are severe or not improving. Because that routing is protocol-driven rather than dependent on any individual clinician's judgment in the moment, it holds up consistently as survivors move between oncology, primary care, and supportive services over time — which is exactly where guidance like this has historically broken down.
This is the same operational logic that already applies across late-effects surveillance: the clinical guidance is rarely the hard part. The hard part is making sure a documented risk factor reliably produces a screening prompt and a next step, months or years later, regardless of which clinician is in the room. Programs that build that connectivity once can extend it to cognitive impairment alongside bone health, cardiovascular risk, and other late effects — without a new workflow, a new spreadsheet, or new staff for every symptom guidelines eventually catch up to.
If your survivorship program is looking to build structured, protocol-driven screening for cognitive impairment or other late effects without adding operational burden, we'd welcome a conversation about how a scalable, evidence-based survivorship platform can help.
Sources
Zhang Y, Kesler SR, Dietrich J, Chao HH. "Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists." JCO Oncology Practice. 2025;21(10):1377-1381. https://ascopubs.org/doi/10.1200/OP-24-00953
Ayoson J, Schneider N, Casanova B, et al. "Beyond survival: a cross-sectional analysis of guideline recommendations for cognitive, sexual, and psychological problems in adult cancer survivors." Scientific Reports. 2026;16:61527. https://pubmed.ncbi.nlm.nih.gov/42463902/
Cognitive Impairment in Adults With Cancer (PDQ®) – Health Professional Version. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/side-effects/memory/cognitive-impairment-hp-pdq
Lange M, Licaj I, Clarisse B, et al. "Cognitive complaints in cancer survivors and expectations for support: Results from a web-based survey." Cancer Medicine. 2019;8(5):2654-2663. https://pmc.ncbi.nlm.nih.gov/articles/PMC6536919/
Myklebost SB, Bevan KG, Gulseth R, Hauken MA, Sekse RJT, Nordgreen T. "Cancer survivors' attitudes toward service delivery formats for interventions targeting cognitive impairments: a survey study." BMC Health Services Research. 2026;26:271. https://link.springer.com/article/10.1186/s12913-025-13981-2